Short Interest in Genmab A/S (NASDAQ:GMAB) Grows By 40.0%

Genmab A/S (NASDAQ:GMAB) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, a growth of 40.0% from the February 13th total of 1,650,000 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is presently 1.7 days.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. Finally, Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its holdings in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC raised its holdings in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the period. Barclays PLC lifted its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

Shares of GMAB stock opened at $20.80 on Tuesday. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.02. The firm has a market capitalization of $13.76 billion, a price-to-earnings ratio of 11.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The business has a 50 day simple moving average of $21.22 and a 200 day simple moving average of $22.33.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.